Masooma S Rana

ORCID: 0000-0003-1731-085X
Publications
Citations
Views
---
Saved
---
About
Contact & Profiles
Research Areas
  • Myeloproliferative Neoplasms: Diagnosis and Treatment
  • Eosinophilic Disorders and Syndromes
  • Multiple Myeloma Research and Treatments
  • Hemoglobinopathies and Related Disorders
  • Monoclonal and Polyclonal Antibodies Research
  • Chronic Myeloid Leukemia Treatments
  • BRCA gene mutations in cancer
  • Acute Myeloid Leukemia Research
  • Cancer Mechanisms and Therapy
  • Genomics and Rare Diseases
  • CAR-T cell therapy research
  • Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
  • Cardiac tumors and thrombi
  • Kruppel-like factors research
  • Cancer therapeutics and mechanisms
  • Blood disorders and treatments
  • Advances in Oncology and Radiotherapy
  • Mental Health Treatment and Access
  • Ethics in Clinical Research
  • Complement system in diseases
  • Renal Diseases and Glomerulopathies
  • Synthesis and Biological Evaluation
  • Amyloidosis: Diagnosis, Treatment, Outcomes
  • Hematopoietic Stem Cell Transplantation
  • Cancer Genomics and Diagnostics

Stanford University
2024-2025

Mayo Clinic in Arizona
2025

Mayo Clinic
2023-2024

WinnMed
2024

Aga Khan University
2021-2024

Good Samaritan Hospital
2024

Summary Among 301 newly diagnosed patients with acute myeloid leukaemia receiving venetoclax and a hypomethylating agent, 23 (7.6%) experienced major cardiac complications: 15 cardiomyopathy, 5 non‐ST elevation myocardial infarction and/or 7 pericarditis/effusions. Four had more than one complication. Baseline characteristics included median age ± interquartile range; 73 years; 87% males; 96% cardiovascular risk factors; 90% preserved baseline ejection fraction. In multivariate analysis,...

10.1111/bjh.19325 article EN British Journal of Haematology 2024-02-04

The main objective of the current study was to provide a detailed account on prognostic relevance abnormal karyotype (AK) and associated specific cytogenetic abnormalities in polycythemia vera (PV). 669 PV patients were informative, which 436 (65%) evaluated within 1 year diagnosis. Karyotype 67 (15%) patients, including isolated loss Y chromosome (-Y; N=15; 3%), +9 (N=11; del(20q) (N=10; 2%), +8 (N=4; 1%). AK correlated with older age (p

10.3324/haematol.2025.287569 article EN cc-by-nc Haematologica 2025-03-27

Outcomes of bispecific antibodies in patients with renal impairment (RI) are not well-characterized given the exclusion these from clinical trials. Herein, we evaluated relapsed/refractory multiple myeloma and RI treated standard-of-care teclistamab. was defined as creatinine clearance (CrCl) <40mL/min. CrCl <30mL/min or dialysis dependence were severe RI. Of 384 included patients, 81 (21%) had RI, including 45 (18%) 18 (5%) on dialysis. Patients more likely to be older (median...

10.1182/bloodadvances.2025016059 article EN cc-by-nc-nd Blood Advances 2025-04-08

Introduction: Standardized screening, objective evaluation, and management of behavioral health conditions are major challenges in primary care. The Generalized Anxiety Disorder Scale (GAD-7), Patient Health Questionnaire (PHQ-9), Mood (MDQ) provide standardized screening symptom tools for generalized anxiety disorder (GAD), depressive (MDD), Disorders (MD), respectively. This study explores family physicians’ knowledge, attitudes, practices regarding the utilization GAD-7, PHQ-9, MDQ...

10.1177/21501319231224711 article EN cc-by-nc Journal of Primary Care & Community Health 2024-01-01

Abstract Health care professionals (HCP) play an important role in the practical application of genetic screening tests but often feel inadequately prepared for cancer testing (CGT) clinical care. As complexity gene related malignancies increases, it demands HCPs’ preparedness to cater patients’ needs. Therefore, our study aimed assess knowledge, attitude, and practices HCPs Pakistan regarding genetics. A cross-sectional survey was conducted from April 2022 June amongst at a private...

10.21203/rs.3.rs-2127849/v1 preprint EN cc-by Research Square (Research Square) 2022-10-06
Coming Soon ...